Should I get liquid biopsy / multi-cancer early detection?

Our read is that liquid biopsy tests for multi-cancer early detection are well supported, offering a manual trade-off between sensitivity and specificity akin to PSA testing. These tests hold potential for detecting micro-metastatic disease by measuring contributions from multiple deposits.

However, their utility is dependent on stratifying populations by genetic risk, as their usefulness varies within different risk cohorts.

• 01Peter Attia claims (4x) that liquid biopsy tests can allow for a manual trade-off between sensitivity and specificity, similar to PSA testing cutoffs.
• 02Peter Attia claims (1x) that a blood test, like a liquid biopsy, could potentially detect micro-metastatic disease by measuring contributions from multiple deposits.
• 03Peter Attia claims (1x) that liquid biopsies should be used as confirmatory tests, not as primary screening candidates, once other assessments are completed.
• 04Peter Attia claims (1x) that the utility of screening tests, including liquid biopsies, is dependent on stratifying populations by genetic risk, as their usefulness varies within different risk cohorts.

Peter Attia raises a significant concern (1x) regarding the subsequent course of action if a liquid biopsy indicates pancreatic cancer.

The verdict could change with further expert consensus on the appropriate follow-up actions for positive liquid biopsy results, especially for hard-to-treat cancers, or new data on their efficacy as primary screening tools across diverse populations.